Shaheen SM, Saleh AK, Okasha NK, Abdalhamid MA, Fakhry HM, Guindy RR. Implementation of a Regional
STEMI Network in North Cairo (Egypt): Impact on The
Management and Outcome of STEMI Patients. Global Heart.2023; 18(1): 2. DOI: https://t.co/QC3mtGgj64
🚨| NEW: Mohamed Salah becomes the FIRST African player on record to register a FIFA World Cup goal involvement on their birthday (since 1966). 🌟🇪🇬
Salah assisted Egypt's opening goal against Belgium on his 34th birthday.
[@OptaJoe]
ONE OF THE LATEST PUBLICATIONS ON THE MANAGEMENT OF OBESITY IN GENERAL AND SPECIFICALLY AMONG CARDIAC PATIENTS SUCH AS THOSE WITH OBESITY RELATED HFPEF. CARDIOLOGISTS SOON WILL BE HEAVILY INVOLVED IN THE USE OF SEMAGLUTIDE (OZEMPIC) AND TERZEPATIDE (MOUNJARO).
The population is >80 yo, in nursing facility, and SBP <130 on 2 or more antiHTNives. Reducing meds (if no cross-indications like B- blocker for tachycardia) was safe.
Overall, this looks like a pretty limited population eligible for de-escalation.
#ESCCongress
Great late breaker presentation by @mmamas1973
1️⃣ SURMOUNT-5 (72 weeks, n=751): 🔻 Tirzepatide led to superior weight reduction vs semaglutide 🔻 Greater improvements in SBP (-10.2 vs -7.7 mmHg) & LDL (-7.8 vs -5.9 mg/dL)
2️⃣ Post-hoc SURMOUNT-5 analysis: 📉 Lower predicted 10-yr CVD risk with tirzepatide vs semaglutide 🌍 Projection: millions of preventable primary CVD events globally
3️⃣ Real-world & data align: ✅ Tirzepatide linked with lower risk of MI, stroke, & all-cause mortality ✅ Potential 2M preventable CVD events over 10 years with tirzepatide vs 1.5M with semaglutide
4️⃣ Key takeaway:
In adults with obesity (no diabetes/CVD), tirzepatide may provide greater CVD risk reduction than semaglutide.
@mirvatalasnag@DBelardoMD
Just out at #ESCCongress: Our ESC–EAPCI Atlas of Interventional Cardiology shows —
1️⃣ PCI makes up >90% of all CV interventions
2️⃣ Lower-income regions are closing the gap in primary PCI
3️⃣ But the gap in valve interventions is widening”
link to paper here:
https://t.co/c1idVEuJxu
Please that UK data is part of this
#ESC2025
#ESCCongressVisuals for Hotline 1:
Will targeted serum potassium levels further optimize outcomes in patients who received an ICD? Check out the results of the POTCAST Study.👇
Will a Zio Patch monitor permit better detection of AF following continuous rhythm tracing for two weeks? AMALFI Trial will answer this question.👇
Based on the decades old DIG trial, we abandoned Digoxin. A long overdue evaluation of the role of Digoxin in patients with Heart Failure is reported in the more contemporary DIGIT-HF trial.👇
The DOUBLE-CHOICE Study discusses anesthesia strategies for patients undergoing TAVI using self-expanding platforms. Will a minimalistic approach show equivalent outcomes?👇
#ESCCongress #ESCCongressVisuals